Rep. Julie Johnson Sells Bristol Myers Squibb Company (NYSE:BMY) Shares

by · The Cerbat Gem

Representative Julie Johnson (D-Texas) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
  • Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded down $1.32 during trading hours on Friday, hitting $55.30. 13,696,698 shares of the company’s stock were exchanged, compared to its average volume of 12,768,820. The stock has a market capitalization of $112.58 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 9.15 and a beta of 0.29. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company’s 50-day moving average price is $51.91 and its 200-day moving average price is $48.13. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BMY shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Seven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.86.

View Our Latest Stock Report on Bristol Myers Squibb

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after buying an additional 1,058,803 shares during the period. State Street Corp increased its holdings in Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after acquiring an additional 1,855,238 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares during the period. Geode Capital Management LLC grew its position in shares of Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after purchasing an additional 723,459 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth $1,554,154,000. Institutional investors own 76.41% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Recommended Stories